BSD Medical Hyperthermia Systems Featured at the Society for Thermal Medicine Annual Conference Conference highlighted potential use of thermal therapy and ablation as a trigger for an anti-cancer immune response, which could be a key approach in future cancer therapy Business Wire SALT LAKE CITY -- June 5, 2014 BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced BSD hyperthermia systems were featured in multiple presentations at the 31^st Annual Conference of the Society for Thermal Medicine (STM). There were many presentations during the conference regarding innovative uses of thermal therapy in the treatment of patients with a variety of cancers. A keynote lecture by Gosse Adema Ph.D., Department of Tumor Immunology, Radboud University, The Netherlands titled, “Local Tumor Ablation plus Immune Stimulation: Towards in situ Cancer Vaccines,” addressed the use of thermal therapy and ablation therapy as a trigger for an anti-cancer immune response. Professor Adema reported that thermal therapy can trigger the immune response and stimulate the creation of dendritic cells, which can be used to destroy cancer cells. Professor Adema concluded that the use of thermal and ablation therapy to trigger an anti-cancer immune response could be a key approach in future cancer therapy. Douglas Kelly, Michael Payne, Edwin Watts, James Flynn, David Simon, Tyler Gutschenritter, and Matt Weaver, Cancer Treatment Centers of America, Tulsa, gave a presentation on the use of regional hyperthermia to treat cervical carcinoma. They reported on the use of the BSD-2000 Hyperthermia System (BSD-2000) to treat 15 cervical cancer patients. Of the evaluable patients, the overall responses (complete response plus partial response) included 4/4 (100%) for newly diagnosed patients and 6/9 (67%) for recurrent patients. The researchers stated, "The authors have found hyperthermia to be a useful addition to the radiation management of cervical carcinoma." Payne, Kelly, Simon, Gutschenritter, Flynn, Weaver and Oneita Taylor, Cancer Treatment Centers of America, Tulsa, presented a poster on the use of the BSD-2000 to treat 10 patients with unresectable, locally advanced, pelvic tumors. The researchers reported, "In sum, the results of the initial evaluation of this study are encouraging and provide motivation for continual inquiry into the utilization of hyperthermia as an adjuvant standard of care in patients with pelvic tumors." About the BSD-2000 Hyperthermia System The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com. This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information. Contact: BSD Medical Corporation William Barth, 801-972-5555 firstname.lastname@example.org fax: 801-972-5930
BSD Medical Hyperthermia Systems Featured at the Society for Thermal Medicine Annual Conference
Press spacebar to pause and continue. Press esc to stop.